Evidence map›Paper›PMID 26300003›Full record

ArticleOncogene2016

Dysregulated CRTC1 activity is a novel component of PGE2 signaling that contributes to colon cancer growth.

Y Schumacher, T Aparicio, S Ourabah, F Baraille, A Martin, P Wind, R Dentin, C Postic, S Guilmeau

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 41 citations in OpenAlex.

  1. Review
  2. Article
  3. Nutrients · 2024
    Article
  4. Article
  5. CRTC1 is a potential target to delay aging-induced cognitive deficit by protecting the integrity of the blood-brain barrier via inhibiting inflammation.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2023
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Assessment of colon cancer molecular mechanism: a system biology approach.Gastroenterology and hepatology from bed to bench · 2021
    Article
  19. PTGES/PGEOncogene · 2020
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Y SchumacherInserm U1016, Institut Cochin, Paris, France.
T AparicioGastroenterology and Digestive Oncology Unit, Avicenne Hospital, HUPSSD, APHP, Université Paris 13, Bobigny, France.
S OurabahInserm U1016, Institut Cochin, Paris, France.
F BarailleInserm U1016, Institut Cochin, Paris, France.
A MartinPathology Unit, Avicenne Hospital, HUPSSD, APHP, Université Paris 13, Bobigny, France.
P WindDigestive Surgery Unit, Avicenne Hospital, HUPSSD, APHP, Université Paris 13, Bobigny, France.
R DentinInserm U1016, Institut Cochin, Paris, France.
C PosticInserm U1016, Institut Cochin, Paris, France.
S GuilmeauInserm U1016, Institut Cochin, Paris, France.
Centre National de la Recherche Scientifique · FRUniversité Paris Cité · FRUniversité Sorbonne Paris Nord · FRAssistance Publique – Hôpitaux de Paris · FRDélégation Paris 5 · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

First identified as a dedicated CREB (cAMP response element-binding protein) co-activator, CRTC1 (CREB-regulated transcription co-activator 1) has been widely implicated in various neuronal functions because of its predominant expression in the brain. However, recent evidences converge to indicate that CRTC1 is aberrantly activated in an expanding number of adult malignancies. In this study, we provide strong evidences of enhanced CRTC1 protein content and transcriptional activity in mouse models of sporadic (APC(min/+) mice) or colitis-associated colon cancer azoxymethane/dextran sulfate sodium (AOM/DSS-treated mice), and in human colorectal tumors specimens compared with adjacent normal mucosa. Among signals that could trigger CRTC1 activation during colonic carcinogenesis, we demonstrate that treatment with cyclooxygenase 2 (COX2) inhibitors reduced nuclear CRTC1 active form levels in colonic tumors of APC(min/+) or AOM/DSS mice. In accordance, prostaglandins E2 (PGE2) exposure to human colon cancer cell lines promoted CRTC1 dephosphorylation and parallel nuclear translocation, resulting in enhanced CRTC1 transcriptional activity, through EP1 and EP2 receptors signaling and consecutive calcineurin and protein kinase A activation. In vitro CRTC1 loss of function in colon cancer cell lines was associated with reduced viability and cell division rate as well as enhanced chemotherapy-induced apoptosis on PGE2 treatment. Conversely, CRTC1 stable overexpression significantly increased colonic xenografts tumor growth, therefore demonstrating the role of CRTC1 signaling in colon cancer progression. Identification of the transcriptional program triggered by enhanced CRTC1 expression during colonic carcinogenesis, revealed some notable pro-tumorigenic CRTC1 target genes including NR4A2, COX2, amphiregulin (AREG) and IL-6. Finally, we demonstrate that COX2, AREG and IL-6 promoter activities triggered by CRTC1 are dependent on functional AP1 and CREB transcriptional partners. Overall, our study establishes CRTC1 as new mediator of PGE2 signaling, unravels the importance of its dysregulation in colon cancer and strengthens its use as a bona fide cancer marker.

Indexed as

Signal TransductionCarcinogenesisCell Line, TumorCell ProliferationColonic NeoplasmsCyclic AMP Response Element-Binding ProteinDinoprostoneHumansReceptors, Prostaglandin E, EP1 SubtypeReceptors, Prostaglandin E, EP2 SubtypeTranscription Factor AP-1Transcription FactorsCRTC1 protein, humanCyclic AMP Response Element-Binding ProteinDinoprostoneReceptors, Prostaglandin E, EP1 SubtypeReceptors, Prostaglandin E, EP2 SubtypeTranscription Factor AP-1Transcription Factors

Identifiers

PMID26300003
OpenAlexW1163643844

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.